Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on March 14, 2022. The filing reports a specific corporate governance event regarding the appointment and departure of principal officers, effective in April and May 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the transition of the Senior Vice President and Controller role:
- Departure: Ms. Karen Murphy Santiago will leave the Company by May 1, 2022.
- Appointment: Ms. Sharon Greenlees will be appointed Senior Vice President and Controller, effective April 25, 2022.
Management Commentary and Risks
Ms. Greenlees brings extensive experience from AbbVie Inc., where she served as Vice President and Controller, R&D Finance and Operations, and previously held roles in Supply Chain Finance, Pricing, and Investor Relations. She holds a B.S. in Accounting and is a Certified Public Accountant. The filing states there are no family relationships between Ms. Greenlees and any director or executive officer, and she is not a party to any arrangement regarding her selection or any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Confirm the effective date of Ms. Greenlees' appointment (April 25, 2022) and Ms. Santiago's departure (May 1, 2022).
- Verify Ms. Greenlees' prior tenure and roles at AbbVie Inc. as disclosed.
- Review subsequent filings for any financial impact related to the transition of the Controller role.